Syndicate Room

About Syndicate Room

SyndicateRoom Ltd is a Cambridge-headquartered UK venture capital manager headquartered at Wellington House on East Road in Cambridge. The business was founded in September 2013 by Gonçalo de Vasconcelos and Tom Britton, who met at Cambridge Judge Business School. The firm is authorised and regulated by the Financial Conduct Authority. The firm originally operated as a regulated equity-crowdfunding platform offering investor co-investment alongside lead angels, then pivoted in September 2019 to its current model: a single managed Enterprise Investment Scheme fund called Access EIS, with current chief executive Graham Schwikkard credited as the architect of the data-driven thesis behind that pivot. Assets under management are not formally disclosed as a single figure, but the fund has executed 161 portfolio investments since 2019 with retail investor commitments deployed across rolling 12-month cohorts. The firm runs a small number of vehicles: the flagship Access EIS fund, a Carry Back EIS and an SEIS-stage variant.

Investment thesis

SyndicateRoom Access EIS is a data-driven broadly diversified UK early-stage venture strategy built around co-investment with a curated cohort of Super Angels (individual investors identified through public-registry data analysis as the top 0.06 percent of UK angel performers with proven portfolio track records). The fund mandates that every cheque be a co-investment alongside one of those Super Angels, on the same terms and at the same time, sidestepping adverse selection problems that typically plague retail venture vehicles. Sectors are deliberately broad: the Access portfolio spans consumer (food and drink, fashion), B2B SaaS, fintech, medtech and surgical devices, sustainability and B2B marketplaces. Geography is UK-only, a hard constraint of EIS-qualifying status. Ticket sizes per investor start at a GBP 5,000 minimum subscription with fund-level cheques into individual portfolio companies typically small (sub-GBP 500,000) given the deliberate 30-to-50-plus company diversification target per cohort. The limited partner base is UK-resident high-net-worth and sophisticated retail investors using EIS reliefs. Value creation is engineered through statistical diversification rather than active operational support.

Recent activity

Recent disclosed investments include Tred in consumer fintech (2024), Nivoda in B2B marketplace and jewellery-tech (2020 cohort with follow-ons through 2024), R.A.D. Future in consumer and fashion (2021 cohort), MOTH Drinks in consumer and beverages (2020 cohort), Good and Proper Tea in consumer and beverages and Osstec in medtech and surgical devices. The fund publishes monthly investment summaries on its website with seven new portfolio companies added in November to December 2024. Recent exits are not disclosed at the level of detail required (sector plus year) in primary sources, with cohort-level valuation uplifts reported instead (2020 cohort plus 35.1 percent, 2021 cohort plus 48.2 percent as of late 2024). The platform continues to deploy across UK Seed and Series A early-stage investments through the Super Angel co-investment model. Detailed buyer names and multiple data available on Pro at €29/month.